Cy
CymaBay (Gilead)
Newark CAFounded 2003100 employees
Private CapbiotechAcquiredHepatology
Platform: Seladelpar PBC
Market Cap
N/A
All Drugs
4
Clinical Trials
6
Failed / Terminated
3
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| CYM-2446 | CYM-2446 | Phase 2/3 | 2 | MET | EoEPsoriasis | ||
| Tirazanubrutinib | CYM-2367 | NDA/BLA | 2 | MET | SchizophreniaNB | ||
| Niracilimab | CYM-1426 | Phase 1 | 1 | JAK2 | Narcolepsy | ||
| Zanutenlimab | CYM-410 | Phase 2 | 1 | CFTR | IgANMM |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (5)